Discovery of TIGIT-Targeted Small Molecules as Cancer Therapies

Yuxuan Liu

doi:10.29013/esr-26-3.4-3-18

April 30, 2026European Science ReviewOpen Access

Discovery of TIGIT-Targeted Small Molecules as Cancer Therapies

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to identify small molecules that target the immune checkpoint TIGIT, potentially offering new cancer therapies.
Employed machine learning to identify potential binding sites on TIGIT.
Conducted pharmacophore tests to evaluate binding requirements for inhibitors.
Identified several small molecules that effectively bind to TIGIT.
Demonstrated the potential of these inhibitors in modulating immune responses against cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Assesses TIGIT-targeted therapies in cancer, suggesting new treatment options.

Abstract

This paper will discuss the results of experiments done on the immune checkpoint TIGIT and the discovery of potential immune checkpoint inhibitors that can bind to it. First, machine learning was used to find potential binding spots on TIGIT and the requirements it needs to bind. Next came the pharmacophore test

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yuxuan Liu (2026) studied this question.

synapsesocial.com/papers/6a16898b0c924ddd1bd58385 https://doi.org/10.29013/esr-26-3.4-3-18

View Full Paper

Ask AI

Bookmark

Share

Discovery of TIGIT-Targeted Small Molecules as Cancer Therapies

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Discovery of TIGIT-Targeted Small Molecules as Cancer Therapies

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading